Receptor antagonists with distinct selectivity, affinity, and half-life in vivo have been identified and are being used to modulate branches of the AVP physiological responses in cardiac and renal disease, as well as to relieve neurological symptoms and ameliorate the social difficulties in borderline personality disorder. The gene discussed is AVP; the disease is kidney disorder.